Protocol for H.P. Acthar Gel in Moderately to Severely Active Psoriatic Arthritis
Status:
Unknown status
Trial end date:
2014-11-01
Target enrollment:
Participant gender:
Summary
Psoriatic arthritis is a heterogeneous chronic inflammatory disorder involving joints, tendon
sheaths, entheses, and the axial skeleton as well as skin and nails. This is an open-label
trial with H.P. Acthar Gel (80 units/1mL) Subcutaneous injection administered twice weekly.
To evaluate the signs and symptoms of psoriatic arthritis after 12 weeks, including American
College of Rheumatology 20,Clinical Disease Activity Index, Disease Activity Index 28,
Dactylitis and adverse events.